<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015543</url>
  </required_header>
  <id_info>
    <org_study_id>MMH_01</org_study_id>
    <nct_id>NCT05015543</nct_id>
  </id_info>
  <brief_title>Physical Training in Glioblastoma Patients During Cytotoxic Therapy</brief_title>
  <acronym>MMH</acronym>
  <official_title>Glioblastoma and Sports - Does a Personal Training Program Improve Physical Performance and Quality of Life of Brain Tumor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is the prospective controlled use of physical activity in a&#xD;
      collective of patients with glioblastoma after surgery and concomitant radiation/chemotherapy&#xD;
      and during adjuvant cytotoxic therapy. The research question is whether physical exercise is&#xD;
      feasible and whether patients benefit physically and mentally from the activities performed.&#xD;
      For this purpose, specific training units under the supervision of a certified trainer and&#xD;
      sports scientist as well as standardized sports medical test procedures are implemented.&#xD;
      Beyond the instructed training, general physical activity phases are recorded electronically&#xD;
      using a pedometer/activity tracker, which is worn at all times.&#xD;
&#xD;
      It will be examined whether the individual training program&#xD;
&#xD;
        1. improves physical fitness&#xD;
&#xD;
        2. increases quality of life/life satisfaction throughout the intervention&#xD;
&#xD;
        3. can be detected in blood due to increased concentrations of brain-derived neurotrophic&#xD;
           factor 1 (BDNF-1) (voluntary)&#xD;
&#xD;
      The measurements should be taken before and 8, 16 and 24 weeks after the start of training.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The personal trainers of the university clinics in Bochum and Homburg/Saar receive specific&#xD;
      training activities from Münster's trainer Ralf Brandt in order to ensure a standardized&#xD;
      concept. This way, a comparison of the trainings' conduction and recording is possible both&#xD;
      quantitatively and qualitatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in Physical Performance according to Physical Work Capacity (PWC) Test</measure>
    <time_frame>Between week 0 and 16.</time_frame>
    <description>Evidence of a significant increase (at least 15%) in physical work [watt/kilogram bodyweight] at PWC75% of maximum heart rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical Work Capacity (PWC)</measure>
    <time_frame>Between week 0 and 16 (and 24).</time_frame>
    <description>PWC stratified according to:&#xD;
age (&lt;40, 40-60, &gt;60 years)&#xD;
Karnofsky performance status (KPS) (70-80 vs. 90-100 %)&#xD;
Gender&#xD;
PWC test 130, 150, (170)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PWC</measure>
    <time_frame>after 8, 16 and 24 weeks</time_frame>
    <description>changes over time, follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spiroergometry - maximal oxygen consumption (VO2max)</measure>
    <time_frame>Between week 0 and 16 (and 24).</time_frame>
    <description>Changes in the maximal oxygen consumption (measured during spiroergometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spiroergometry - lactate</measure>
    <time_frame>Between week 0 and 16 (and 24).</time_frame>
    <description>Changes in the individual anaerobic lactate threshold (measured during spiroergometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ-C30 Brain module</measure>
    <time_frame>Between week 0 and 16 (and 24).</time_frame>
    <description>Changes in Health Related Quality of Life (HRQoL) using a standardized questionnaire; The EORTC QLQ-C30 questionnaire contains 30 questions and assesses the quality of life of oncology patients multidimensionally across 10 subscales. Times of measurement in week 0, 4, 8, 16, 20 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distress Thermometer (DT)</measure>
    <time_frame>Between week 0 and 16 (and 24).</time_frame>
    <description>Changes in Health Related Quality of Life (HRQoL) using a standardized questionnaire; scale from 1 (not stressed at all) to 10 (extremly stressed); Times of measurement in week 0, 4, 8, 16, 20 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Between week 0 and 16 (and 24).</time_frame>
    <description>Changes in Health Related Quality of Life (HRQoL) using a standardized questionnaire; The Hospital Anxiety and Depression Scale (HADS) is a self-rating scale developed to assess psychological distress in non-psychiatric patients. It consists of two subscales, anxiety and depression (14 items); Times of measurement in week 0, 4, 8, 16, 20 and 24.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Patients paticipating in the Personal Training Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study patients complete two training sessions per week (60 minutes each) under supervision (16 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Personal Training Program</intervention_name>
    <description>One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.</description>
    <arm_group_label>Patients paticipating in the Personal Training Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed glioblastoma&#xD;
&#xD;
          -  Karnofsky Index ≥ 70&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) ≤ 2&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Completed surgical therapy&#xD;
&#xD;
          -  Completed radiation and chemotherapy&#xD;
&#xD;
          -  Thrombocytes &gt; 50.000/µl&#xD;
&#xD;
          -  Hb &gt; 8 mg/dl&#xD;
&#xD;
          -  Ability to give consent&#xD;
&#xD;
          -  Mother tongue German/very good German skills&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed dementia (Mini-Mental-State-Test &lt; 24/30 points)&#xD;
&#xD;
          -  Pain (strong, permanent, restricting movement)&#xD;
&#xD;
          -  Impairment of consciousness&#xD;
&#xD;
          -  Fever&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Insufficiently adjusted epilepsy (despite anticonvulsive therapy &gt; 3 focal seizures&#xD;
             per day or &gt; 1 generalized seizure in the previous 3 days)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothee Wiewrodt, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Münster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorothee Wiewrodt, PD Dr. med.</last_name>
    <phone>+49 251 83 48305</phone>
    <email>dorothee.wiewrodt@ukmuenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johanna Jost, M.Ed.</last_name>
    <email>johanna.jost@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothee Wiewrodt, PD Dr. med.</last_name>
      <phone>+492518348305</phone>
      <email>dorothee.wiewrodt@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Johanna Jost, M.Ed.</last_name>
      <email>johanna.jost@ukmuenster.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sports</keyword>
  <keyword>Glioblastoma (GBM)</keyword>
  <keyword>physical training</keyword>
  <keyword>Quality of Life (QOL)</keyword>
  <keyword>Neuro-Oncology</keyword>
  <keyword>Psycho-Oncology</keyword>
  <keyword>fitness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

